In the last trading session, 1,234,574 TCR2 Therapeutics Inc. (NASDAQ:TCRR) shares changed hands as the company’s beta touched 0. With the company’s per share price at $21.41 changed hands at -$1.85 or -0.08% during last session, the market valuation stood at $816.52 Million. TCRR’s last price was a discount, traded about -67.49% off its 52-week high of $35.86. The share price had its 52-week low at $6.4, which suggests the last value was 70.11% up since then. When we look at TCR2 Therapeutics Inc.’s average trading volume, we note the 10-day average is 835.54 Million shares, with the 3-month average coming to 494.35 Million.
Analysts gave the TCR2 Therapeutics Inc. (TCRR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.7. If we narrow down to specifics, the data shows that none out of 9 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, none recommended TCRR as a Hold, 9 felt it is a Buy and none rated the stock as Underweight. TCR2 Therapeutics Inc.’s EPS for the current quarter is expected to be -$0.52.
TCR2 Therapeutics Inc. (NASDAQ:TCRR) trade information
Although TCRR has turned red as seen at the end of in last trading. With action -7.95%, the performance over the past five days has been red. The jump to weekly highs of $24.33 on Friday, Mar 26 added 12% to the stock’s daily price. The company’s shares are showing year-to-date downside of -0.31%, with the 5-day performance at -0.09% in the red. However, in the 30-day time frame, TCR2 Therapeutics Inc. (NASDAQ:TCRR) is -0.19% down. Looking at the short shares, we see there were 3.29 Million shares sold at short interest cover period of 0.01 days.
The consensus price target for the stock as assigned by Wall Street analysts is $45.67, meaning bulls need an upside of 113.31% from its current market value. According to analyst projections, TCRR’s forecast low is $34 with $57 as the target high. To hit the forecast high, the stock’s price needs a +166.23% upsurge from its current level, while the stock would need to tank 58.8% for it to hit the projected low.
TCR2 Therapeutics Inc. (TCRR) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 0%. The 2021 estimates are for TCR2 Therapeutics Inc. earnings to increase by 48.1%, but the outlook for the next 5-year period is at 0% per year.
TCR2 Therapeutics Inc. (NASDAQ:TCRR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.57% of TCR2 Therapeutics Inc. shares while 96.72% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 98.25%. There are 133 institutions holding the TCR2 Therapeutics Inc. stock share, with MPM Asset Management, LLC the top institutional holder. As of Dec 30, 2020, the company held 10.62% of the shares, roughly 4.05 Million TCRR shares worth $125.29 Million.
Wellington Management Group, LLP holds the second largest percentage of outstanding shares, with 9.84% or 3.75 Million shares worth $116.09 Million as of Dec 30, 2020.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Among Mutual Funds, the top two as of Dec 30, 2020 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 618446 shares estimated at $19.13 Million under it, the former controlled 1.62% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.62% of the shares, roughly 616.8 Thousand shares worth around $16.32 Million.